BOSTON--(BUSINESS WIRE)--Sengenics announced the launch of a new autoantibody profiling service – the ‘Pan-Autoimmune Protein Array 1.0’ – to expedite the identification and quantitation of autoantibody disease biomarker signatures. The service is a protein microarray-based, multiplexed immunoassay which utilizes Sengenics’ KREX® protein folding technology and optimized computational analysis. The protein microarray comprises 110 known autoantigens reported in the literature to be associated with a wide range of autoimmune diseases. This focused content affords a cost- and time-effective, quantitative solution to researchers who wish to investigate new autoantibody signatures in specific autoimmune diseases, as well as to those interested in exploring the intersection between autoimmune diseases and cancers.
“We have curated this focused collection of autoimmune disease-associated autoantigens through results obtained from internal research and data mining efforts. Autoantibodies are known to mark out disease-associated changes in many disorders, including autoimmune diseases, cancers and neurological disorders. Multiplexed autoantibody signatures thus provide a means for early disease diagnosis, for stratification of patients according to disease sub-types, as well as for differentiation of patients with similar clinical symptoms but different underlying etiologies. In the autoimmune disease space, autoantibody signatures discovered using Sengenics technology can, for example, separate SLE patients into distinct sub-types and can also differentiate between Sjögren's disease and non-Sjögren's Sicca, whilst identifying other potentially confounding underlying autoimmune syndromes. I therefore believe that this technology can be a powerful new tool in the work of researchers who are studying the role of autoantibody responses in autoimmune diseases, as well as in the broader immunology field,” says Sengenics CSO, Professor Jonathan Blackburn.
The launch of the Pan-Autoimmune Protein Array 1.0 will expand the breadth of assay options designed to better serve customers.
About Sengenics
Sengenics is a precision medicine company working to improve patient outcomes through physiologically relevant, data-guided decision making. Our solutions enable the discovery and validation of autoantibody biomarker signatures for patient stratification, therapeutic response prediction and development of companion diagnostics.
